Lumenis files to raise $115m on Nasdaq


The laser surgical devices company plans to hold the IPO in the first quarter of 2014.

Lumenis Ltd., a developer of lasers for minimally invasive surgical procedures, has filed a prospectus with the US Securities and Exchange Commission (SEC) to raise $115 million on Nasdaq. The company did not disclose the company value for the offering, but it will reportedly be held at $450-500 million, after money. In November, "Globes" reported that the company planned to raise $100 million in an IPO soon.

Lumenis plans to hold the IPO in the first quarter of 2014, but it may bring the date forward if the market climate is suitable. Goldman Sachs, Credit Suisse, Jefferies and Wells Fargo Securities are the joint bookrunners on the deal.

Viola Partners owns 45.9% of Lumenis and XT Group Ltd. (formerly Ofer Holdings Ltd.), owns 35.5%. They will not convert shares in the offering, but may offer the underwriters shares as part of an over-allotment option. Israel's Agate Medical Investments LP and Sky Fund also owns stakes in Lumenis.

In the prospectus, Lumenis stated that it had $194.3 million in sales in January-September 2013, 7% more than in the corresponding quarter of 2012, and that its net profit rose 655% to $12.7 million. The company had $38 million in cash at the end of September.

Lumenis develops medical devices that are mainly based on lasers. It has three divisions: medical aesthetics; laser surgery, and ophthalmology. Surgical devices are the company's biggest activity, 39% of the total, followed by aesthetic devices at 37.5%, and ophthalmic devices at 23.4%. Surgical devices have increased as a proportion of the company's business at the expense of aesthetic devices. In January-September, 34.8% of sales were in the Americas, 15% in Japan, 32% in the rest of the Asia-Pacific region (which also has the fastest growth), and 17% were in Europe.

Even for a company like Lumenis, with a turnover of hundreds of millions dollars, raising $115 million is a very ambitious target. In its favor are the company's rapid growth in the past year, and the success of its management and owners in turning it around from losses to profits.

Published by Globes [online], Israel business news - - on December 8, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

View comments in rows
Update by email about comments talkback
Your name
Please insert your name
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Biolight jumps on strong Zacks recommendation

Zacks cites the company for its technology, products, and meeting its targets.

VBL Therapeutics raises $40m in revived Nasdaq IPO

After the fiasco of the failed IPO in August, the drug development company scaled down the offering.

Assuta Hospital Gov't plans taxing private hospitals

The tax is one of the recommendations of the Economic Arrangments bill.

Erez Vigodman Teva boosted by European drug recommendations

Teva's share jumped 4% in Tel Aviv, after climbing 4.9% on Wall Street.

Partner/Orange Partner launches smartphone medical services

The new services includes prescriptions, hospital referrals, and confirmation of illness.

Reuven Krupik Clal Biotech unit PolyHeal nears licensing deal

PolyHeal has signed an MOU with a European drug company for an exclusive global license.

Nasdaq Galmed jumps on FDA hepatitis drug approval

The FDA awarded Fast Track Designation to aramchol for the treatment of Non-Alcoholic Steato-Hepatitis.

artificial sweeteners Weizmann Inst: Sweeteners cause diabetes, obesity

A study found that artificial sweeteners adversely affect intestinal bacteria.

BioCancell share jumps on positive cancer trial results

The clinical trials demonstrated safety and effectiveness of the treatment on high-risk bladder cancer patients.

Trendlines Group set for Toronto IPO

The technological incubators company is raising C$9 at a company value of C$80 million, after money.

Reuven Krupik Clal Biotech sues Hyperion for $200m

Clal Biotechnology alleges Hyperion made "rash and ill-considered" decisions in the Andromeda affair.

pharmaceuticals Clal Biotech: No evidence of misconduct by us

Clal Biotech says documents it was shown by Hyperion do not indicate it committed any misconduct regarding Andromeda.

Soroka Hospital  picture: Eyal Yitzhar Visiting Israel’s wounded at Soroka

Soroka Medical Center in Beersheva, the Israeli hospital closest to Gaza, bears the medical brunt of Operation Protective Edge.

Twitter Facebook Linkedin RSS Newsletters גלובס